JP2017519762A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519762A5 JP2017519762A5 JP2016573549A JP2016573549A JP2017519762A5 JP 2017519762 A5 JP2017519762 A5 JP 2017519762A5 JP 2016573549 A JP2016573549 A JP 2016573549A JP 2016573549 A JP2016573549 A JP 2016573549A JP 2017519762 A5 JP2017519762 A5 JP 2017519762A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- polypeptide
- human
- composition according
- vwf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 229920001184 polypeptide Polymers 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 108010047303 von Willebrand Factor Proteins 0.000 claims 13
- 102100036537 von Willebrand factor Human genes 0.000 claims 13
- 229960001134 von willebrand factor Drugs 0.000 claims 13
- 230000000694 effects Effects 0.000 claims 10
- 102000043853 ADAMTS13 Human genes 0.000 claims 9
- 108091005670 ADAMTS13 Proteins 0.000 claims 9
- 230000008816 organ damage Effects 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 230000006378 damage Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000000302 ischemic effect Effects 0.000 claims 5
- 239000003550 marker Substances 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 2
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 101000798281 Homo sapiens A disintegrin and metalloproteinase with thrombospondin motifs 13 Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 102000057210 human ADAMTS13 Human genes 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2013007A NL2013007B1 (en) | 2014-06-16 | 2014-06-16 | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| NL2013007 | 2014-06-16 | ||
| US201462030817P | 2014-07-30 | 2014-07-30 | |
| US62/030,817 | 2014-07-30 | ||
| PCT/EP2015/063493 WO2015193326A1 (en) | 2014-06-16 | 2015-06-16 | Methods of treating ttp with immunoglobulin single variable domains and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020014229A Division JP7105260B2 (ja) | 2014-06-16 | 2020-01-30 | 免疫グロブリン単一可変ドメインでｔｔｐを処置する方法、およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519762A JP2017519762A (ja) | 2017-07-20 |
| JP2017519762A5 true JP2017519762A5 (enExample) | 2019-01-17 |
| JP6688746B2 JP6688746B2 (ja) | 2020-04-28 |
Family
ID=51541255
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016573549A Active JP6688746B2 (ja) | 2014-06-16 | 2015-06-16 | 免疫グロブリン単一可変ドメインでｔｔｐを処置する方法、およびその使用 |
| JP2020014229A Active JP7105260B2 (ja) | 2014-06-16 | 2020-01-30 | 免疫グロブリン単一可変ドメインでｔｔｐを処置する方法、およびその使用 |
| JP2022110921A Pending JP2022160431A (ja) | 2014-06-16 | 2022-07-11 | 免疫グロブリン単一可変ドメインでｔｔｐを処置する方法、およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020014229A Active JP7105260B2 (ja) | 2014-06-16 | 2020-01-30 | 免疫グロブリン単一可変ドメインでｔｔｐを処置する方法、およびその使用 |
| JP2022110921A Pending JP2022160431A (ja) | 2014-06-16 | 2022-07-11 | 免疫グロブリン単一可変ドメインでｔｔｐを処置する方法、およびその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US10858445B2 (enExample) |
| EP (6) | EP3366305B1 (enExample) |
| JP (3) | JP6688746B2 (enExample) |
| KR (2) | KR102403388B1 (enExample) |
| CN (1) | CN106559985A (enExample) |
| AU (2) | AU2015276237B2 (enExample) |
| CA (1) | CA2952103A1 (enExample) |
| ES (5) | ES2915473T3 (enExample) |
| IL (1) | IL249540B (enExample) |
| NL (1) | NL2013007B1 (enExample) |
| PL (5) | PL3335724T3 (enExample) |
| PT (5) | PT3335724T (enExample) |
| RU (1) | RU2704444C2 (enExample) |
| SG (2) | SG10201811109PA (enExample) |
| WO (1) | WO2015193326A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| CN107340225B (zh) * | 2017-07-13 | 2019-07-05 | 徐州医科大学 | 一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法 |
| MY204220A (en) * | 2018-02-06 | 2024-08-16 | Ablynx Nv | Methods of treating initial episode of ttp with immunoglobulin single variable domains |
| MX2023005661A (es) * | 2020-11-18 | 2023-05-26 | Green Cross Corp | Variante de adamts13 que tiene actividad o velocidad de escape incrementada contra un autoanticuerpo. |
| AU2022345251A1 (en) | 2021-09-17 | 2024-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies |
| CN118715246A (zh) * | 2021-12-10 | 2024-09-27 | 李人浩 | 结合血管性血友病因子(vwf)a1结构域或自动抑制模块的多肽、变体及其用途 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB335768A (en) | 1929-10-24 | 1930-10-02 | Jacoviac Maurice | Improvements in protecting devices for gramophone disc records |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5043429B1 (en) | 1987-05-01 | 1997-10-14 | Scripps Research Inst | Protein fragments containing factor VIII binding domain of von willebrand factor |
| FI903489A0 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna. |
| EP1498427B1 (en) | 1992-08-21 | 2009-12-16 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| JP2002535993A (ja) | 1999-02-05 | 2002-10-29 | リイクスニフェルシタイト ライデン | 組換え体細胞における代謝物の生合成を変調する方法 |
| AU6322900A (en) | 1999-08-02 | 2001-02-19 | Keygene N.V. | Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| AU2003251238A1 (en) | 2002-08-07 | 2004-02-25 | Umc Utrecht Holding B.V. | Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha |
| EP1565482B1 (en) | 2002-10-23 | 2014-04-30 | Ludwig Institute for Cancer Research Ltd. | A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same |
| RU2524129C2 (ru) | 2003-01-10 | 2014-07-27 | Аблинкс Н.В. | Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами |
| RU2357974C2 (ru) | 2003-01-10 | 2009-06-10 | Аблинкс Н.В. | Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами |
| US7461263B2 (en) | 2003-01-23 | 2008-12-02 | Unspam, Llc. | Method and apparatus for a non-revealing do-not-contact list system |
| JP2007521234A (ja) | 2003-08-12 | 2007-08-02 | ウィリアム エム ヤーブロー | 尋常性ざ瘡の治療薬及び使用方法 |
| US7270976B2 (en) * | 2004-07-19 | 2007-09-18 | American Diagnostica, Inc. | Methods for measuring ADAMTS13 activity and protein on platelets and in plasma |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| AU2005293752A1 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease |
| PL1836500T3 (pl) | 2005-01-14 | 2010-12-31 | Ablynx Nv | Sposoby i testy do rozróżniania między różnymi postaciami chorób i zaburzeń cechujących się małopłytkowością i/lub samoistną interakcją między czynnikiem von Willebranda (vWF) a płytkami krwi |
| DK2444424T3 (en) * | 2005-05-20 | 2018-12-03 | Ablynx Nv | IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| CA2678218A1 (en) | 2007-02-21 | 2008-08-28 | Ablynx N.V. | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization |
| AU2008252853B2 (en) | 2007-05-24 | 2011-12-01 | Ablynx N.V. | Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders |
| EP2252303A2 (en) | 2008-03-21 | 2010-11-24 | Ablynx NV | Von willebrand factor specific binders and methods of use therefor |
| KR20110079693A (ko) | 2008-10-29 | 2011-07-07 | 와이어쓰 엘엘씨 | 단일 도메인 항원 결합 분자의 정제 방법 |
| EP2362767B1 (en) | 2008-10-29 | 2017-12-06 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
| EP2506874A1 (en) | 2009-12-01 | 2012-10-10 | Ablynx N.V. | Von willebrand factor specific binding agents and uses thereof |
| BR112013011176A2 (pt) * | 2010-11-05 | 2020-09-01 | Novartis Ag | métodos de tratamento de artrite reumatoide usando antagonistas de il-17 |
| SI2717905T1 (sl) | 2011-06-10 | 2018-09-28 | Baxalta GmbH | Obravnava bolezni koagulacije z dajanjem rekombinantnega vwf |
| PH12014500380A1 (en) | 2011-08-17 | 2022-05-02 | Glaxo Group Ltd | Modified proteins and peptides |
| NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| MY204220A (en) | 2018-02-06 | 2024-08-16 | Ablynx Nv | Methods of treating initial episode of ttp with immunoglobulin single variable domains |
-
2014
- 2014-06-16 NL NL2013007A patent/NL2013007B1/en active
-
2015
- 2015-06-16 US US15/319,467 patent/US10858445B2/en active Active
- 2015-06-16 PT PT181536749T patent/PT3335724T/pt unknown
- 2015-06-16 ES ES18153673T patent/ES2915473T3/es active Active
- 2015-06-16 ES ES18153674T patent/ES2924199T3/es active Active
- 2015-06-16 ES ES18153671T patent/ES2843642T3/es active Active
- 2015-06-16 PT PT157298290T patent/PT3154569T/pt unknown
- 2015-06-16 PT PT181536764T patent/PT3332800T/pt unknown
- 2015-06-16 CN CN201580040020.4A patent/CN106559985A/zh active Pending
- 2015-06-16 EP EP18153671.5A patent/EP3366305B1/en active Active
- 2015-06-16 PT PT181536731T patent/PT3335723T/pt unknown
- 2015-06-16 KR KR1020177001152A patent/KR102403388B1/ko active Active
- 2015-06-16 PL PL18153674.9T patent/PL3335724T3/pl unknown
- 2015-06-16 JP JP2016573549A patent/JP6688746B2/ja active Active
- 2015-06-16 EP EP18153673.1A patent/EP3335723B1/en active Active
- 2015-06-16 EP EP18153676.4A patent/EP3332800B1/en active Active
- 2015-06-16 WO PCT/EP2015/063493 patent/WO2015193326A1/en not_active Ceased
- 2015-06-16 PL PL15729829T patent/PL3154569T3/pl unknown
- 2015-06-16 ES ES15729829T patent/ES2881331T3/es active Active
- 2015-06-16 PL PL18153673.1T patent/PL3335723T3/pl unknown
- 2015-06-16 SG SG10201811109PA patent/SG10201811109PA/en unknown
- 2015-06-16 PL PL18153671T patent/PL3366305T3/pl unknown
- 2015-06-16 CA CA2952103A patent/CA2952103A1/en not_active Abandoned
- 2015-06-16 ES ES18153676T patent/ES2831865T3/es active Active
- 2015-06-16 EP EP22172948.6A patent/EP4059513A1/en not_active Withdrawn
- 2015-06-16 PL PL18153676T patent/PL3332800T3/pl unknown
- 2015-06-16 SG SG11201610488QA patent/SG11201610488QA/en unknown
- 2015-06-16 PT PT181536715T patent/PT3366305T/pt unknown
- 2015-06-16 EP EP15729829.0A patent/EP3154569B1/en active Active
- 2015-06-16 AU AU2015276237A patent/AU2015276237B2/en active Active
- 2015-06-16 EP EP18153674.9A patent/EP3335724B1/en active Active
- 2015-06-16 RU RU2017100077A patent/RU2704444C2/ru active
- 2015-06-16 KR KR1020227012546A patent/KR102568585B1/ko active Active
-
2016
- 2016-12-13 IL IL249540A patent/IL249540B/en unknown
-
2018
- 2018-01-26 US US15/880,978 patent/US12269893B2/en active Active
- 2018-01-26 US US15/881,055 patent/US20180155443A1/en not_active Abandoned
- 2018-01-26 US US15/881,003 patent/US10919980B2/en active Active
- 2018-01-26 US US15/880,870 patent/US20180155440A1/en not_active Abandoned
-
2020
- 2020-01-30 JP JP2020014229A patent/JP7105260B2/ja active Active
-
2021
- 2021-05-03 AU AU2021202747A patent/AU2021202747B2/en active Active
-
2022
- 2022-07-11 JP JP2022110921A patent/JP2022160431A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519762A5 (enExample) | ||
| JP2020002171A5 (enExample) | ||
| JP2017503820A5 (enExample) | ||
| JP2018111728A5 (enExample) | ||
| JP2018184417A5 (enExample) | ||
| JP2015529225A5 (enExample) | ||
| JP2018193377A5 (enExample) | ||
| JP2015517488A5 (enExample) | ||
| JP2020518599A5 (enExample) | ||
| JP2016512248A5 (enExample) | ||
| JP2015518818A5 (enExample) | ||
| JOP20200156A1 (ar) | إيسكيتامين لعلاج الاكتئاب | |
| JP2019519519A5 (enExample) | ||
| JP2014515763A5 (enExample) | ||
| JP2016516016A5 (enExample) | ||
| JP2016529255A5 (enExample) | ||
| JP2017031213A5 (enExample) | ||
| FI3227675T3 (fi) | Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi | |
| JP2018509388A5 (enExample) | ||
| JP2014169326A5 (enExample) | ||
| JP2020521797A5 (enExample) | ||
| JP2018505882A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| JP2019528285A5 (enExample) | ||
| JP2017533972A5 (enExample) |